ABVX Stock — ABIVAX Société Anonyme

ABIVAX Société Anonyme (ABVX)

Updated October 16, 2026.

ABVX is a Stock. Total return is 659.7% over the past 3 years, 574.1 points ahead of SPY at 85.6%.

ABIVAX Société Anonyme is a clinical-stage biotechnology company headquartered in Paris that develops immunotherapeutic treatments for chronic inflammatory diseases, with its lead candidate obefazimod currently in Phase 3 trials for ulcerative colitis and Phase 2b trials for Crohn's disease. The company does not currently have an established distribution schedule. This security appeals primarily to investors with high risk tolerance seeking exposure to early-stage drug development in the immunology space.

ABVX performance versus SPY

Price and return data through 2026-10-16.

Total return is 659.7% over the past 3 years, 574.1 points ahead of SPY at 85.6%. Over the past year its total return — price change plus distributions reinvested — is -5.1%. Its deepest 1-year drawdown was 50.1%.

ABVX key facts

Asset type

Stock

Asset class

Equity

Inception date

10/19/2023

Distribution frequency

None

Last close

$88.13 (as of 2026-10-16)

Market cap

$7,691,239,498

Average volume

1430198.0

Beta

-0.232

Payout ratio

0.0%

EPS

$-6.02

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABVX risks and drawbacks

The deepest 1-year drawdown on record here is 50.1%.

Who may consider ABVX — and who may not

It is a weaker fit for investors who need monthly cash flow (ABVX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ABVX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions